Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors.

ABSTRACT:

Objectives

Reliable predictive biomarkers for response to immune checkpoint inhibition (ICI) are lacking. Pretreatment serum albumin, a known prognostic and predictive factor in ICI-treated patients, has been proposed as a potential pharmacokinetic surrogate marker for anti-PD1/PD-L1 antibodies, as it shares a homeostatic pathway with IgG. However, this hypothesis is currently based on theoretical considerations and limited evidence from retrospective data. Therefore, we comprehensively investigated the prognostic and predictive value of pretreatment albumin and its relationship with anti-PD-L1 IgG levels.

Methods

We analysed pretreatment albumin and atezolizumab serum levels and clinical response in four trials (IMvigor210, IMvigor211, IMmotion151 and OAK) of patients with

SUBMITTER: Saal J 

PROVIDER: S-EPMC10632074 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature